The 6th annual conference will capture expert insights by focusing on new pathways with novel vaccines and immunotherapies.
LONDON, UNITED KINGDOM, May 22, 2017 /EINPresswire.com/ — The market for cancer vaccines is comparatively smaller than other cancer therapy categories. The market size can be attributed to the emerging stages of industry life cycle and the late introduction of vaccines in the market. Many global companies are actively investing in cancer vaccine development in hopes of attaining market leverage. *
Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2017 will provide the ideal interactive platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy. The 6th annual conference will capture expert insights by focusing on new pathways with novel vaccines and immunotherapies, drug formulations, personalised treatments in addition to immune check-point inhibitors, and much more.
Day 1 will address topics on tumour cell immunotherapy, combination therapies, and defining successful treatment, while Day 2 explores preclinical development, new approaches to cancer vaccines, and enhancing cancer vaccine efficacy.
If you haven’t seen the new and improved agenda for Cancer Vaccines 2017, visit the event website to view the detailed programme and full speaker line-up.
There is currently an £300 early bird discount for all registrations made before May 31st 2017. For more registration details please visit www.cancervaccinesevent.com/ein
6th annual Cancer Vaccines Conference
27th – 28th September 2017
Follow the conversation on Twitter and LinkedIn at #cancervac17
SMi Group Ltd
+44 (0)20 7827 6012
email us here